Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

This study has been withdrawn prior to enrollment.
National Cancer Institute (NCI)
Information provided by:
Alliance for Clinical Trials in Oncology Identifier:
First received: May 9, 2009
Last updated: July 11, 2013
Last verified: February 2013

RATIONALE: Collecting and storing samples of blood, bone marrow, and DNA from other tissues from patients with cancer to study in the laboratory may help in the study of cancer.

PURPOSE: This laboratory study is collecting and storing blood, bone marrow, and other samples from patients with acute leukemia, chronic leukemia, or myelodysplastic syndromes.

Condition Intervention
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Other: biologic sample preservation procedure

Study Type: Observational
Official Title: The CALGB Leukemia Tissue Bank

Resource links provided by NLM:

Further study details as provided by Alliance for Clinical Trials in Oncology:

Primary Outcome Measures:
  • Collection and storage of specimens from newly diagnosed patients with acute or chronic leukemia or myelodysplastic syndromes enrolled on a CALGB protocol [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: May 1996
Detailed Description:


  • Collect and store specimens from newly diagnosed patients with acute or chronic leukemia or myelodysplastic syndromes enrolled on a CALGB protocol.

OUTLINE: This is a multicenter study.

Bone marrow aspirate and blood specimens are obtained from patients at diagnosis, remission, or relapse and stored. Buccal smears are obtained at diagnosis, and DNA is extracted and preserved.

PROJECTED ACCRUAL: Samples from approximately 1,500 patients will be collected for this study within 5 years.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • One of the following diagnoses:

    • Acute leukemia
    • Chronic leukemia
    • Myelodysplastic syndrome
  • Newly diagnosed disease
  • Enrolled on a CALGB treatment protocol
  • Must enroll on this study before receiving any therapy for malignancy


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00899223

  Show 142 Study Locations
Sponsors and Collaborators
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Study Chair: Michael A. Caligiuri, MD Ohio State University Comprehensive Cancer Center
  More Information

Publications: Identifier: NCT00899223     History of Changes
Other Study ID Numbers: CDR0000271412  U10CA031946  CALGB-9665 
Study First Received: May 9, 2009
Last Updated: July 11, 2013
Health Authority: Unspecified

Keywords provided by Alliance for Clinical Trials in Oncology:
accelerated phase chronic myelogenous leukemia
acute lymphocytic leukemia
acute undifferentiated leukemia
blastic phase chronic myelogenous leukemia
chronic myelomonocytic leukemia
chronic phase chronic myelogenous leukemia
meningeal chronic myelogenous leukemia
progressive hairy cell leukemia, initial treatment
prolymphocytic leukemia
stage 0 chronic lymphocytic leukemia
stage I adult T-cell leukemia/lymphoma
stage I chronic lymphocytic leukemia
stage II adult T-cell leukemia/lymphoma
stage II chronic lymphocytic leukemia
stage III adult T-cell leukemia/lymphoma
stage III chronic lymphocytic leukemia
stage IV adult T-cell leukemia/lymphoma
stage IV chronic lymphocytic leukemia
untreated adult acute lymphoblastic leukemia
untreated adult acute myeloid leukemia
untreated childhood acute lymphoblastic leukemia
untreated childhood acute myeloid leukemia and other myeloid malignancies
untreated hairy cell leukemia
de novo myelodysplastic syndromes
myelodysplastic/myeloproliferative neoplasm, unclassifiable
secondary myelodysplastic syndromes
secondary acute myeloid leukemia
juvenile myelomonocytic leukemia
childhood myelodysplastic syndromes

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions processed this record on April 27, 2016